Latest: FDA Approves New Biosimilar for Oncology Treatment

Case-Based Approach to Initial Treatment Planning for IDH-Mutant Gliomas

0 Mins
Panelists discuss how to counsel a 38-year-old patient with excellent surgical outcome about treatment options, weighing the benefits of early IDH inhibitor therapy against watchful waiting while considering individual patient factors and goals.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago